Aditxt ADTX shares are trading higher on Thursday after the company secured CLIA certification for AditxtScore laboratory operations in Richmond and plans to launch AditxtScore for COVID-19 as a lab developed test.
Aditxt Therapeutics is a pre-clinical stage life sciences company that focuses on prolonging life and enhancing life quality of transplanted patients. The firm develops products designed to induce tolerance to transplanted organs.
Aditxt shares were trading up 5.96% at $2.04 at the time of publication on Thursday. The stock has a 52-week range between $9.58 and $1.62.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
